Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis

Malena Cohen-Cymberknoh, Noa Gilead, Silvia Gartner, Sandra Rovira, Hannah Blau, Huda Mussaffi, Joseph Rivlin, Michal Gur, Michal Shteinberg, Lea Bentur, Galit Livnat, Micha Aviram, Elie Picard, Ariel Tenenbaum, Shoshana Armoni, Oded Breuer, David Shoseyov, Eitan Kerem

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Eradication of Pseudomonas aeruginosa (PA) is critical in cystic fibrosis (CF) patients. Objectives To determine eradication success rate of newly acquired PA and to identify characteristics associated with eradication failure. Methods In an observational study, data from patients with newly acquired PA infection from 2007 to 2013 were collected. Clinical variables were compared in patients with and without successful eradication for ≥ 1 year. Results Of 183 patients out of 740 (25%) from 7 CF Centers that had newly acquired PA, eradication succeeded in 72%. Patients with the highest risk of failure had multi-resistant PA, fewer sputum cultures taken, were older, and were diagnosed at a later age. The risk of eradication failure increased by 1.3% with each year of delayed CF diagnosis; successful eradication increased by 17% with each additional sputum culture taken. Conclusions Delayed detection of PA infection leading to delayed treatment and growth of multi-resistant organisms is associated with eradication failure.

Original languageEnglish
Pages (from-to)776-782
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number6
StatePublished - 1 Nov 2016
Externally publishedYes


  • Cystic fibrosis
  • Eradication failure
  • Pseudomonas infection

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis'. Together they form a unique fingerprint.

Cite this